216 related articles for article (PubMed ID: 7448778)
1. Classification of antineoplastic agents by their selective toxicities toward oxygenated and hypoxic tumor cells.
Teicher BA; Lazo JS; Sartorelli AC
Cancer Res; 1981 Jan; 41(1):73-81. PubMed ID: 7448778
[TBL] [Abstract][Full Text] [Related]
2. Classification of antineoplastic treatments by their differential toxicity toward putative oxygenated and hypoxic tumor subpopulations in vivo in the FSaIIC murine fibrosarcoma.
Teicher BA; Holden SA; al-Achi A; Herman TS
Cancer Res; 1990 Jun; 50(11):3339-44. PubMed ID: 2334928
[TBL] [Abstract][Full Text] [Related]
3. Effects of anthracyclines on oxygenated and hypoxic tumor cells.
Kennedy KA; Siegfried JM; Sartorelli AC; Tritton TR
Cancer Res; 1983 Jan; 43(1):54-9. PubMed ID: 6401171
[TBL] [Abstract][Full Text] [Related]
4. Cytotoxicity and DNA lesions produced by mitomycin C and porfiromycin in hypoxic and aerobic EMT6 and Chinese hamster ovary cells.
Fracasso PM; Sartorelli AC
Cancer Res; 1986 Aug; 46(8):3939-44. PubMed ID: 3089583
[TBL] [Abstract][Full Text] [Related]
5. Effects of antineoplastic agents and hyperthermia on cytotoxicity toward chronically hypoxic glioma cells.
Watanabe M; Tanaka R; Hondo H; Kuroki M
Int J Hyperthermia; 1992; 8(1):131-8. PubMed ID: 1545159
[TBL] [Abstract][Full Text] [Related]
6. Porfiromycin as a bioreductive alkylating agent with selective toxicity to hypoxic EMT6 tumor cells in vivo and in vitro.
Keyes SR; Rockwell S; Sartorelli AC
Cancer Res; 1985 Aug; 45(8):3642-5. PubMed ID: 3926306
[TBL] [Abstract][Full Text] [Related]
7. Effect of hypoxia and acidosis on the cytotoxicity of four platinum complexes at normal and hyperthermic temperatures.
Herman TS; Teicher BA; Collins LS
Cancer Res; 1988 May; 48(9):2342-7. PubMed ID: 3356002
[TBL] [Abstract][Full Text] [Related]
8. The response of hypoxic B16 melanoma cells to in vivo treatment with chemotherapeutic agents.
Hill RP; Stanley JA
Cancer Res; 1975 May; 35(5):1147-53. PubMed ID: 1120304
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapeutic attack of hypoxic tumor cells by the bioreductive alkylating agent mitomycin C.
Keyes SR; Heimbrook DC; Fracasso PM; Rockwell S; Sligar SG; Sartorelli AC
Adv Enzyme Regul; 1985; 23():291-307. PubMed ID: 3934922
[TBL] [Abstract][Full Text] [Related]
10. Hypoxia-selective nitrobenzyloxycarbonyl derivatives of 1,2-bis(methylsulfonyl)-1-(2-chloroethyl)hydrazines.
Shyam K; Penketh PG; Shapiro M; Belcourt MF; Loomis RH; Rockwell S; Sartorelli AC
J Med Chem; 1999 Mar; 42(5):941-6. PubMed ID: 10072691
[TBL] [Abstract][Full Text] [Related]
11. Hypoxic cells as specific drug targets for chemotherapy.
Kennedy KA
Anticancer Drug Des; 1987 Oct; 2(2):181-94. PubMed ID: 3130070
[TBL] [Abstract][Full Text] [Related]
12. Preferential activation of mitomycin C to cytotoxic metabolites by hypoxic tumor cells.
Kennedy KA; Rockwell S; Sartorelli AC
Cancer Res; 1980 Jul; 40(7):2356-60. PubMed ID: 7388797
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic attack of hypoxic cells of solid tumors: presidential address.
Sartorelli AC
Cancer Res; 1988 Feb; 48(4):775-8. PubMed ID: 3123053
[TBL] [Abstract][Full Text] [Related]
14. Modification of the metabolism and cytotoxicity of bioreductive alkylating agents by dicoumarol in aerobic and hypoxic murine tumor cells.
Keyes SR; Rockwell S; Sartorelli AC
Cancer Res; 1989 Jun; 49(12):3310-3. PubMed ID: 2470504
[TBL] [Abstract][Full Text] [Related]
15. Mitomycin C: a prototype bioreductive agent.
Sartorelli AC; Hodnick WF; Belcourt MF; Tomasz M; Haffty B; Fischer JJ; Rockwell S
Oncol Res; 1994; 6(10-11):501-8. PubMed ID: 7620218
[TBL] [Abstract][Full Text] [Related]
16. Activity of C-7 substituted cyclic acetal derivatives of mitomycin C and porfiromycin against hypoxic and oxygenated EMT6 carcinoma cells in vitro and in vivo.
Rockwell S; Keyes SR; Loomis R; Kelley M; Vyas DM; Wong H; Doyle TW; Sartorelli AC
Cancer Commun; 1991 Jun; 3(6):191-8. PubMed ID: 2049227
[TBL] [Abstract][Full Text] [Related]
17. Studies on the mechanism of the cytotoxic action of the mitomycin antibiotics in hypoxic and oxygenated EMT6 cells.
Sartorelli AC; Tomasz M; Rockwell S
Adv Enzyme Regul; 1993; 33():3-17. PubMed ID: 8356915
[TBL] [Abstract][Full Text] [Related]
18. Preferential kill of hypoxic EMT6 mammary tumor cells by the bioreductive alkylating agent porfiromycin.
Sartorelli AC; Belcourt MF; Hodnick WF; Keyes SR; Pritsos CA; Rockwell S
Adv Enzyme Regul; 1995; 35():117-30. PubMed ID: 7572339
[TBL] [Abstract][Full Text] [Related]
19. Effects of RSR13 and oxygen on the cytotoxicity of cisplatin and carboplatin to EMT6 mouse mammary tumor cells in vitro and in vivo.
Donnelly ET; Kelley M; Rockwell S
Cancer Chemother Pharmacol; 2004 Jan; 53(1):43-50. PubMed ID: 14574460
[TBL] [Abstract][Full Text] [Related]
20. Hypoxic fraction and binding of misonidazole in EMT6/Ed multicellular tumor spheroids.
Franko AJ
Radiat Res; 1985 Jul; 103(1):89-97. PubMed ID: 4070561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
